Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Ambulatory Electronic Health Record (EHR) market is expected to reach $8.16 billion by 2026 growing at a CAGR of 7.8% during 2019 to 2026. Ambulatory EHR are the systems which help the physicians to maintain an electronic-based data of patients to track their medical records and long-term care. This is a digital version of the patient s paper chart which is known as electronic health record (EHR). Using these systems, detailed and specific information about each patient is collected and complete documentation of their health is recorded.
The information includes medical history, allergies and medication, the status of immunization, personal statistics, laboratory test results, demographics, and others. This software is mainly used by healthcare professionals in their clinics and hospitals to maintain the medical records of their patients. These systems are bifurcated based on the practice size i.
Monday, December 21, 2020
In a year where the use of “unprecedented” became routine, COVID-19 dominated just about every aspect of life, and its impact on drug and device law was no less encompassing. As we bid adieu and good riddance to 2020, we pause, once again, to reflect on the most significant legal developments for our drug and device clients this year. Below is a brief recap and assessment of our top five developments in drug and device law for the year.
1. Snap Removal Continues Its Momentum
In April, the Fifth Circuit Court of Appeals joined the Second and Third Circuits in upholding snap removal. Snap removal occurs when an action is removed from state court to federal court before a forum defendant is served, and it is premised on a plain reading of 28 U.S.C. § 1441(b)(2).